Efficacy, Safety, and Immunogenicity of HLX02 Compared with Reference Trastuzumab in Patients with Recurrent or Metastatic HER2-Positive Breast Cancer: A Randomized Phase III Equivalence Trial

BACKGROUND: HLX02 is an approved biosimilar of trastuzumab. OBJECTIVE: This study aimed to evaluated the efficacy, safety, and immunogenicity of HLX02 compared with reference trastuzumab in patients with human epidermal growth factor receptor 2 (HER2)-positive recurrent or metastatic breast cancer....

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:BioDrugs
Autori principali: Xu, Binghe, Zhang, Qingyuan, Sun, Tao, Li, Wei, Teng, Yue’e, Hu, Xichun, Bondarenko, Igor, Adamchuk, Hryhoriy, Zhang, Liangming, Trukhin, Dmytro, Wang, Shusen, Zheng, Hong, Tong, Zhongsheng, Shparyk, Yaroslav, Wang, Qingyu
Natura: Artigo
Lingua:Inglês
Pubblicazione: Springer International Publishing 2021
Soggetti:
Original Research Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC8084805/
https://ncbi.nlm.nih.gov/pubmed/33826080
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40259-021-00475-w
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi